The posterior probability error-rate estimates (Fukunaga and Kessell 1973; Glick 1978; Hora and Wilcox 1982) for each group are based on the posterior probabilities of the observations classified into ...
The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies.